Biofrontera Inc 预计于2026年第三季度提交四肢、颈部和躯干适应症的补充新药申请

美股速递
Feb 17

Biofrontera Inc 计划在2026年第三季度向监管机构提交一份补充新药申请(sNDA),该申请针对的是其在四肢、颈部和躯干方面的适应症扩展。此举标志着公司在拓展其产品应用范围方面迈出了重要一步,有望为相关患者群体提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10